Uncategorized
2011/12/6: Largest clinical trial of point-of-care DNA testing begins in Italy
“Spartan Bioscience today announced the start of GENE-MATRIX—the largest clinical trial to date of point-of-care DNA testing in medicine. The randomized prospective trial will enroll 4,000 patients over 2 years at up to 40 hospitals in Italy.”
2011/11/3: First clinical trial of point-of-care DNA testing in medicine enables cardiac stent patients to receive personalized antiplatelet therapy
“Spartan Bioscience today announced data from the RAPID GENE study showing that point-of-care DNA testing successfully identified patients carrying the CYP2C19*2 gene at the time of cardiac catheterization. Cardiologists were then able to prescribe antiplatelet therapy according to the patient’s genotype. This personalized medicine approach completely eliminated high on-treatment platelet reactivity (HPR) in CYP2C19*2 carriers.”
2011/5/30: Ontario leads clean water research and innovation
“Spartan Bioscience will develop a rapid, on-site water testing system that will reduce analysis times from 72 hours to 2-4 hours, with significant commercial and environmental applications…Ontario is providing over $2.7M to support Spartan Bioscience, as part of a $7.8M project.”
2011/1/10: Spartan Bioscience announces Alere as exclusive distributor for Germany, Austria and Switzerland
“Spartan Bioscience today announces an exclusive distribution agreement with Alere GmbH for distribution of the Spartan RX CYP2C19 in Germany, Austria and Switzerland…Alere will concentrate its efforts on reaching customers in surgery suites and catheterization labs within hospitals and other medical centers.”
2010/12/20: GenomeWeb. Spartan Bioscience gets CE IVD Mark for ’sample-to-answer’ CYP2C19 testing platform.
“Canada’s Spartan Bioscience said today that its CYP2C19 molecular test, which runs on the company’s Spartan RX PCR-based point-of-care testing platform, has received a CE Mark for in vitro diagnostic use in Europe.”
2010/12/20: Spartan Bioscience announces CE Marking for first point-of-care DNA personalized medicine testing system
“Spartan Bioscience today announced its Spartan RX CYP2C19 received a CE IVD Mark under the European Directive on In Vitro Diagnostic Medical Devices. The CE Mark certification allows commercial distribution in Europe as well as in all countries recognizing the CE Mark in the Middle East, Africa, Latin America, and Asia-Pacific regions.”
Protected: Due Diligence Documents
2010/8/10: Spartan Bioscience announces first point-of-care DNA testing system for personalized medicine
“Spartan Bioscience today announced the availability of the Spartan RX, the first complete sample-to-result, point-of-care DNA testing system for personalized medicine.”
Spartan Bioscience receives the Canadian Advanced Technology Alliance 2010 Award for Outstanding Product Achievement in the ICT/Health Sector
Ottawa, ON, May 20, 2010 - Spartan Bioscience is proud to announce that the company is the recipient of the CATA 2010 Award for Outstanding Product Achievement in the ICT/Health Sector. Sponsored by Wellington West Capital, the award is granted annually by the Canadian Advanced Technology Alliance (CATA) to a Canadian organization for an outstanding engineering development which has resulted in the production of a world-class product or family of products. The product must have proven itself in operation, and its design and market success must enhance Canada’s international reputation for innovation and excellence.
“Spartan is thrilled to win this award. It demonstrates a wider awareness of our achievements among the broad CATA membership,” said Larry D’Andrea, CEO of Spartan Bioscience.
The Spartan DX-12 is the first commercially-available DNA testing system for on-demand applications that is fast, affordable and easy to use. Applications include decentralized testing for infectious diseases, human genetic testing, food safety and water testing.
“These award winners have shown that they are innovators and skilled business people. They are role models for the development of commercially successful enterprises in Canada. CATA’s role as their advocate is to ensure that we create a rich foundation of programs and initiatives that enable leading entrepreneurs to launch their products and exploit their new business opportunities,” said John Reid, President of CATA.
About Spartan Bioscience
Founded in 2005, Spartan Bioscience Inc. is a privately held molecular diagnostics company that develops, manufactures, and markets DNA testing systems for on-demand applications. The company is focusing on decentralized and point-of-care applications where rapid and convenient DNA testing is particularly important, such as pharmacogenetics, infectious diseases, and food and water safety testing.
-30-
For Media and Analyst inquiries, please contact:
Larry D’Andrea
CEO
Spartan Bioscience Inc.
1-613-228-7756 x701
media@spartanbio.com
Spartan Bioscience Founder Dr. Paul Lem receives the Ontario Premier’s 2010 Catalyst Award as Best Young Innovator
Young Scientist Honoured for Spartan DX-12 DNA Testing System
Ottawa, ON, May 18, 2010 – Mr. Larry D’Andrea, CEO, and the Board of Directors of Spartan Bioscience Inc., a Canadian molecular diagnostics company that develops, manufactures, and markets DNA testing systems for on-demand applications, today announced that Dr. Paul Lem is the 2010 recipient of the Ontario Premier’s Catalyst Award as Best Young Innovator.
Dr. Paul Lem, founder of Spartan Bioscience, is one of Canada’s most successful emerging biotechnology entrepreneurs. At age 30, Dr. Lem founded Spartan Bioscience and launched his most notable invention, the Spartan DX-12. This medical device is a DNA testing system that is fast, affordable, and easy to use. It is designed for decentralized applications in fields such as infectious diseases, human genetic testing, food safety, and water testing. Thanks to his drive and creativity, Dr. Lem has put the Spartan DX-12, Spartan Bioscience, and Ontario at the forefront of the rapidly growing worldwide market for on-demand DNA testing.
“We are very proud that Dr. Lem has been honoured with this award,” said Larry D’Andrea, CEO of Spartan Bioscience. “Not only does it acknowledge the innovativeness of Dr. Lem’s invention, but it validates the importance of on-demand DNA testing.”
About Spartan Bioscience
Founded in 2005, Spartan Bioscience Inc. is a privately held molecular diagnostics company that develops, manufactures, and markets DNA testing systems for on-demand applications. The company is focusing on decentralized and point-of-care applications where rapid and convenient DNA testing is particularly important, such as pharmacogenetics, infectious diseases, and food and water safety testing.
-30-
For Media and Analyst inquiries, please contact:
Larry D’Andrea
CEO
Spartan Bioscience Inc.
1-613-228-7756 x701
media@spartanbio.com
